<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02897999</url>
  </required_header>
  <id_info>
    <org_study_id>QBKPN-03</org_study_id>
    <nct_id>NCT02897999</nct_id>
  </id_info>
  <brief_title>Single and Multiple Dose Evaluation of QBKPN SSI In Healthy Volunteers</brief_title>
  <official_title>A Placebo-Controlled, Blinded, Dose-Escalation, Study to Assess the Safety and Pharmacodynamics of Single and Multiple Doses of QBKPN (Inactivated Klebsiella Pneumoniae) Site Specific Immunomodulator (SSI), Administered Subcutaneously to Healthy Male and Female Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qu Biologics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Qu Biologics Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this dose-escalation study is to assess the safety and pharmacodynamics of&#xD;
      single and multiple doses of QBKPN SSI, administered subcutaneously to healthy adult&#xD;
      volunteers&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse events [Safety and Tolerability]</measure>
    <time_frame>2 weeks</time_frame>
    <description>Incidence, severity, and dose-relationship of adverse events, vital signs, and clinical laboratory parameters</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in cellular biomarkers over time</measure>
    <time_frame>2 weeks</time_frame>
    <description>Absolute (#/mL) and Differentials (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunological biomarkers analysis</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>MAD Cohorts only: Changes in cell surface markers on neutrophils and monocytes over time</measure>
    <time_frame>2 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>MAD cohorts only: Gene Expression Analysis</measure>
    <time_frame>2 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Phenotype and Genotype Correlation [Exploratory gene association analysis]</measure>
    <time_frame>2 weeks</time_frame>
  </other_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>SAD Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 0.05 mL QBKPN or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 0.10 mL QBKPN or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 0.20 mL QBKPN or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 0.40 mL QBKPN or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 0.80 mL QBKPN or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 1.2 mL QBKPN or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 doses of QBKPN or Placebo administered every other day (using one of the dose from the SAD Cohort)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 doses of QBKPN or Placebo administered every other day (using one of the dose from the SAD Cohort)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 doses of QBKPN or Placebo administered every day (using one of the dose from the SAD Cohort)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 doses of QBKPN or Placebo administered every day (using one of the dose from the SAD Cohort)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>QBKPN</intervention_name>
    <description>QBKPN Site Specific Immunomodulators</description>
    <arm_group_label>MAD Cohort 1</arm_group_label>
    <arm_group_label>MAD Cohort 2</arm_group_label>
    <arm_group_label>MAD Cohort 3</arm_group_label>
    <arm_group_label>MAD Cohort 4</arm_group_label>
    <arm_group_label>SAD Cohort 1</arm_group_label>
    <arm_group_label>SAD Cohort 2</arm_group_label>
    <arm_group_label>SAD Cohort 3</arm_group_label>
    <arm_group_label>SAD Cohort 4</arm_group_label>
    <arm_group_label>SAD Cohort 5</arm_group_label>
    <arm_group_label>SAD Cohort 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>MAD Cohort 1</arm_group_label>
    <arm_group_label>MAD Cohort 2</arm_group_label>
    <arm_group_label>MAD Cohort 3</arm_group_label>
    <arm_group_label>MAD Cohort 4</arm_group_label>
    <arm_group_label>SAD Cohort 1</arm_group_label>
    <arm_group_label>SAD Cohort 2</arm_group_label>
    <arm_group_label>SAD Cohort 3</arm_group_label>
    <arm_group_label>SAD Cohort 4</arm_group_label>
    <arm_group_label>SAD Cohort 5</arm_group_label>
    <arm_group_label>SAD Cohort 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy, non-smoking (at least for 6 months prior to first study drug administration)&#xD;
             males or females, 18 to 65 years of age, inclusive at the time of informed consent.&#xD;
&#xD;
          -  Body mass index (BMI) that is within 18.5 - 30.0 kg/m2, inclusive.&#xD;
&#xD;
          -  Healthy, according to the medical history, ECG, vital signs, laboratory results and&#xD;
             physical examination&#xD;
&#xD;
          -  Systolic blood pressure between 95-140 mmHg, inclusive, and diastolic blood pressure&#xD;
             between 55-90 mmHg, inclusive, and heart rate between 50-100 bpm, inclusive, unless&#xD;
             deemed otherwise by the PI/Sub-Investigator.&#xD;
&#xD;
          -  QTc interval â‰¤ 450 milliseconds for males and females, unless deemed otherwise Not&#xD;
             Clinically Significant by the Principal Investigator/Sub-Investigator.&#xD;
&#xD;
          -  Availability to volunteer for the entire study duration and willing to adhere to all&#xD;
             protocol requirements.&#xD;
&#xD;
          -  Agree not to have a tattoo or body piercing until the end of the study.&#xD;
&#xD;
          -  Agree to practice effective methods of contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known history or presence of any clinically significant hepatic, renal/genitourinary,&#xD;
             gastrointestinal, cardiovascular, cerebrovascular, pulmonary, endocrine,&#xD;
             immunological, musculoskeletal, neurological, psychiatric, dermatological or&#xD;
             hematological disease or condition unless determined as not clinically significant by&#xD;
             the PI/Sub-Investigator.&#xD;
&#xD;
          -  A known history or positive test result for human immunodeficiency virus (HIV),&#xD;
             chronic Hepatitis B surface antigen, or Hepatitis C.&#xD;
&#xD;
          -  A positive test result for drugs of abuse (marijuana, amphetamines, barbiturates,&#xD;
             cocaine, opiates, phencyclidine and benzodiazepines), alcohol test and cotinine.&#xD;
             Positive pregnancy test for female subjects.&#xD;
&#xD;
          -  Known history or presence of (1) Alcohol abuse or dependence within one year prior to&#xD;
             first study drug administration; (2) Drug abuse or dependence; (3) Known or suspected&#xD;
             hypersensitivity to any component of the product (4) Food allergies and/or presence of&#xD;
             any dietary restrictions; or (5) Severe allergic reactions (e.g. anaphylactic&#xD;
             reactions, angioedema).&#xD;
&#xD;
          -  Recent history (within 8 weeks prior to screening) of travel to or emigration from any&#xD;
             country with high incidence for tuberculosis.&#xD;
&#xD;
          -  A positive tuberculin skin (PPD) test result&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>August 19, 2016</study_first_submitted>
  <study_first_submitted_qc>September 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2016</study_first_posted>
  <last_update_submitted>August 23, 2017</last_update_submitted>
  <last_update_submitted_qc>August 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

